Study of Transcatheter Edge-to-Edge Repair and Other Treatments for Atrial Functional Mitral Regurgitation

What this Trial Is About

Researchers are evaluating outcomes for patients with atrial functional mitral regurgitation who receive different treatments in routine clinical care. This international, multicenter, retrospective registry study aims to compare the results of patients treated with transcatheter edge-to-edge repair, transcatheter mitral valve replacement, or conservative guideline-directed medical therapy. The study focuses on real-world experiences and long-term patient outcomes. Participants are grouped based on the treatment they received mitral valve transcatheter edge-to-edge repair, transcatheter mitral valve replacement, or conservative management with guideline-directed medical therapy. All devices used in these procedures are included. This observational study does not involve assigning treatments but collects data from past clinical care since January 2010. Participants health outcomes are followed for 12 months, including death from any cause and rehospitalization for heart failure. Other measures include the severity of mitral regurgitation, cardiovascular death, unplanned mitral valve interventions, heart failure symptom severity NYHA class III or IV, and physical ability measured by a 6-minute walking test. This long-term follow-up helps researchers understand the effectiveness and safety of the different management approaches.

Assessment of Transcatheter Edge-to-Edge Repair in Atrial Functional Mitral Regurgitation (ATRIAL-MR)